David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Prepare for Phase 2 and a Comeback for Inovio

By David Moadel, InvestorPlace Contributor

Is INO stock nothing more than a post-pandemic pop-and-drop story? Don't count Inovio out as a crucial funding source offers timely support.

Slowly Accumulate Workhorse Stock on the Rebound

By David Moadel, InvestorPlace Contributor

The timing is right to cautiously take a long position in WKHS stock as the last-mile delivery specialist makes headway in the EV space.

With TikTok Reprieve, Fastly’s Comeback Is Already Under Way

By David Moadel, InvestorPlace Contributor

The company's third-quarter fiscal data is far from ideal, but Fastly stock investors can relax as a political roadblock has cleared.

Get a Sweet Deal as Aphria Jumps Head-First into the Beer Biz

By David Moadel, InvestorPlace Contributor

Aphria stock holders have struggled for years, but their troubles may soon be over in the wake of a surprising acquisition.

The Breakthrough for Sorrento Could Be Just Around the Corner

By David Moadel, InvestorPlace Contributor

If you'd like to wager on a company with a packed clinical pipeline featuring potential Covid-19 treatments, SRNE stock is a great choice.

Load More